Lexaria Bioscience (LEXX) Cash from Operations (2010 - 2026)
Lexaria Bioscience's (LEXX) quarterly Cash from Operations came in at 2163872.0 in Q1 2026, down 44.46% year-on-year from 3896147.89 in Q1 2025, and down 119.88% quarter-over-quarter from 984098.0 in Q4 2025.
Lexaria Bioscience (LEXX) Cash from Operations (2010 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Cash from Operations across 17 years of filings, most recently posting 2163872.0 for Q1 2026.
- Cash from Operations for Q1 2026 came in at 2163872.0, down 44.46% year-over-year; the trailing twelve-month figure through Feb 2026 was 9374421.0 (down 27.0% YoY), and the FY2025 annual result was 10450387.0, down 110.74% from the prior year.
- Cash from Operations came in at 2163872.0 for Q1 2026 at Lexaria Bioscience, down from 984098.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 619614.0 in Q1 2024 to a low of 3583953.0 in Q2 2025.
- The 5-year median for Cash from Operations is 1277270.0 (2022), against an average of 1655977.18.
- Peak annual rise in Cash from Operations reached 63.9% in 2025, while the deepest fall reached 183.08% in 2025.
- Lexaria Bioscience's Cash from Operations stood at 1245313.0 in 2022, then advanced by 5.11% to 1181653.0 in 2023, then tumbled by 130.7% to 2726045.0 in 2024, then jumped by 63.9% to 984098.0 in 2025, then tumbled by 119.88% to 2163872.0 in 2026.
- The last three Cash from Operations figures came in at 2163872.0 (Q1 2026), 984098.0 (Q4 2025), and 2642498.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | -2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -2.16 Mn |
| Feb 28, 2026 | -2.16 Mn |
| Nov 30, 2025 | -984,098.00 |
| Nov 30, 2025 | -984,098.00 |
| Aug 31, 2025 | -2.64 Mn |
| Aug 31, 2025 | -2.64 Mn |
| May 31, 2025 | -3.58 Mn |
| May 31, 2025 | -3.58 Mn |
| Feb 28, 2025 | -1.50 Mn |
| Feb 28, 2025 | -1.50 Mn |
| Nov 30, 2024 | -2.73 Mn |
| Nov 30, 2024 | -2.73 Mn |
| Aug 31, 2024 | -1.89 Mn |
| Aug 31, 2024 | -1.89 Mn |
| May 31, 2024 | -1.27 Mn |
| May 31, 2024 | -1.27 Mn |
| Feb 29, 2024 | -619,614.00 |
| Feb 29, 2024 | -619,614.00 |
| Nov 30, 2023 | -1.18 Mn |
| Nov 30, 2023 | -1.18 Mn |